Click here to read the articles and view the interactive digital edition

Pharmaceutical Commerce - April 2025

Vendors are growing, and product and service offerings are expanding.

The Hot Market for Cold Chain Services

How artificial intelligence tools are helping to optimize the pharmaceutical transport process.

An AI-Pharma Transport Collaboration

How pharma manufacturers can steadily navigate GTN components and complexities when planning pharmacy benefit reimbursement.

Popping the Gross-to-Net Bubble, Part III: The Pharmacy Benefit

Articles

Why meaningful content must meet the right audience.

Keys to Advancing HCP Engagement

Videos

In the fourth part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at USC, comments on health policy developments that the pharma supply chain should be aware of.

The Connection Between Pharma Innovation and Health Policy Development

The latest news for pharma industry insiders.

Pharma Pulse 3/3/25: How Tariffs Will Drive Up Pharmaceutical Costs, Medicaid Cuts Could Shift Up to $1.1 Trillion in Costs to States & more

After an initial 30-day pause, the US president plans to re-enact the import taxes on the nation’s trading partners—while also doubling the 10% tariff on China. 

Trump Intends to Impose 25% Tariffs on Canada, Mexico Starting March 4

Podcasts

Tracy Lopez uncovers the fundamentals pertaining to third-party logistics providers.

Selecting the Right 3PL

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at USC, describes how the tariffs can affect price or competition within the branded drug space.

Will Tariffs Affect Branded Drug Prices?

Pharma Pulse 2/28/25: Delivering Personalized Experiences at Scale, Combat Counterfeit Medications & more

The news comes amid the possibility that President Trump imposes a 25% tariff on pharmaceuticals, which could encourage manufacturers to begin reshoring their services.

Lilly to Build Four New US Manufacturing Facilities

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at USC, details the factors that could makes the generic drug market susceptible to supply chain disruptions.

Featured Content

Pharmaceutical Commerce - April 2025

The Hot Market for Cold Chain Services

An AI-Pharma Transport Collaboration

Popping the Gross-to-Net Bubble, Part III: The Pharmacy Benefit